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NOTE
Renovations Needed:
The FDA’s Floor/Ceiling Framework, 
Preemption, and the Opioid Epidemic
Michael R. Abrams*
The FDA’s regulatory framework for pharmaceuticals uses a “floor/ceiling”
model: administrative rules set a “floor” of minimum safety, while state tort 
liability sets a “ceiling” of maximum protection. This model emphasizes pre-
market scrutiny but largely relies on the state common law “ceiling” to police 
the postapproval drug market. As the Supreme Court increasingly holds state 
tort law preempted by federal administrative standards, the FDA’s frame-
work becomes increasingly imbalanced. In the face of a historic prescription-
medication overdose crisis, the Opioid Epidemic, this imbalance allows the 
pharmaceutical industry to avoid internalizing the public health costs of their 
opioid products. This Note argues that the FDA’s administrative design mis-
allocates the costs of the Opioid Epidemic and fails to adequately compensate 
those injured by it. Part I summarizes the FDA’s regulatory framework with 
respect to opioid medications. Part II explains how that framework creates a 
compensatory problem that prevents the internalization of negative external-
ities by pharmaceutical manufacturers. Part III proposes a victims’ compen-
sation fund as the best substitute for the functions long performed by state 
tort liability.
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Introduction
In January of 1980, the New England Journal of Medicine published a let-
ter to the editor penned by Boston University medical researcher Dr. 
Hershel Jick and his assistant Jane Porter.1 The five-sentence letter was titled 
“Addiction Rare in Patients Treated with Narcotics.”2 It reported that of 
11,882 hospitalized patients who received at least one dose of narcotic pain 
killers in the researchers’ files, “there were only four cases of reasonably well 
documented addiction in patients who had no history of addiction.”3 Thus, 
the researchers concluded, “despite widespread use of narcotic drugs in hos-
pitals, the development of addiction is rare in medical patients with no histo-
ry of addiction.”4
The letter, referred to simply as “Porter and Jick,” rose to notoriety.5
Previously, “doctors had long been taught to avoid prescribing highly addic-
tive opioids to patients.”6 But by the 1990s, the letter’s conclusory observa-
tion about opioid addictiveness “was invoked by doctors, academics, phar-
maceutical companies and others as evidence that few users would develop 
1. Jane Porter & Hershel Jick, Correspondence, Addiction Rare in Patients Treated with 
Narcotics, 302 New Eng. J. Med. 123 (1980); Derek Hawkins, How a Short Letter in a Prestig-
ious Journal Contributed to the Opioid Crisis, Wash. Post (June 2, 2017), https://
www.washingtonpost.com/news/morning-mix/wp/2017/06/02/how-the-opioid-crisis-traces-
back-to-a-five-sentence-scholarly-letter-from-1980/ [https://perma.cc/G3M6-LPR9].
2. Porter & Jick, supra note 1.
3. Id.
4. Id.
5. See Sarah Zhang, The One-Paragraph Letter from 1980 That Fueled the Opioid Crisis,
Atlantic (June 2, 2017), https://www.theatlantic.com/health/archive/2017/06/nejm-letter-
opioids/528840/ [https://perma.cc/RWR9-3L86].
6. Sonia Moghe, Opioid History: From ‘Wonder Drug’ to Abuse Epidemic, CNN (Oct. 
14, 2016, 6:41 AM), http://www.cnn.com/2016/05/12/health/opioid-addiction-history/
index.html [https://perma.cc/37BU-78EQ] (“[A]n 11-line letter . . . pushed back on the popular 
thought that using opioids to treat chronic pain was risky.”).
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addictions” to prescription narcotic pain killers.7 An article in Scientific 
American cited Porter and Jick’s one-paragraph letter as an “extensive 
study.”8 Time magazine referred to their “landmark” research as showing the 
“exaggerated fear that patients would become addicted” to prescription opi-
oids was “basically unwarranted.”9 Almost forty years later, the Journal pub-
lished a retrospective “bibliometric analysis” of the letter; this analysis found 
that the letter was cited at least 608 times and that some of these citations 
“grossly misrepresented the conclusions of the letter.”10
Those citations fueled a shift in the healthcare industry’s perspective on 
the treatment of pain.11 Pharmaceutical and healthcare industry figures “ag-
gressively pushed the concept of pain as the fifth vital sign.”12 With the in-
troduction of subjective measures like the “pain scale” and the linking of 
pain treatment to patient satisfaction, new incentives pushed doctors to pre-
scribe narcotic pain killers.13 Concurrently, the pharmaceutical industry 
ramped up promotion of pain medications.14 Purdue Pharma introduced 
OxyContin to the market as a long-term solution to chronic pain.15 A 1998 
OxyContin promotional video featured a doctor referencing the letter’s data: 
7. Hawkins, supra note 1.
8. Ronald Melzack, The Tragedy of Needless Pain, Sci. Am., Feb. 1990, at 27, 29–30.
9. Sam Allis, Less Pain, More Gain, Time (June 24, 2001), http://content.time.com/
time/magazine/article/0,9171,158154,00.html (on file with the Michigan Law Review).
10. Pamela T.M. Leung, et al., Correspondence, A 1980 Letter on the Risk of Opioid Ad-
diction, 376 New Eng. J. Med. 2194, 2194 (2017). Contemporaneously published letters to the 
editor in the Journal were cited, on average, 11 times. Id.
11. See D. Andrew Tompkins et al., Providing Chronic Pain Management in the “Fifth 
Vital Sign” Era: Historical and Treatment Perspectives on a Modern-Day Medical Dilemma, 173 
Drug & Alcohol Dependence S11, S13–S14 (2016) (finding that throughout the 20th century 
“physicians and patients alike had been afraid of developing addiction if placed on morphine 
or other opioids” but that “[d]uring the 1990s and early 2000s, . . . fears of addiction to pre-
scribed opioids were minimized due to an overemphasis on the findings” of Porter and Jick).
12. Brian F. Mandell, Letter from the Editor, The Fifth Vital Sign: A Complex Story of 
Politics and Patient Care, 83 Clev. Clinic J. Med. 400 (2016) (citing Am. Pain Soc’y Quality of 
Care Comm., Quality Improvement Guidelines for the Treatment of Acute Pain and Cancer 
Pain, 274 JAMA 1874 (1995)). This concept posited that pain was undertreated due to a lack of 
reporting and assessment, and called on doctors to measure subjective pain just as they record-
ed heart rate or blood pressure. Id.
13. See, e.g., Nat’l Pharm. Council, Inc. & Joint Comm’n on Accreditation of 
Healthcare Orgs., Pain: Current Understanding of Assessment, Management, and 
Treatments 17, 19–29 (2001) (providing guidelines for the measurement of pain, and citing 
the Porter and Jick letter to state that “[f]ear of causing addiction . . . reflects a lack of under-
standing of the risk of addiction with therapeutic drug use” and that “clinicians often overes-
timate this risk”).
14. Mandell, supra note 12 (“[S]ome drug manufacturers in the early 2000s funded pub-
lications and physician presentations to encourage the expanded use of opioids and other med-
ications for pain control.”); see also Moghe, supra note 6 (“Purdue Pharma took out ads for 
OxyContin in medical journals across the nation in 2000.”).
15. Moghe, supra note 6 (detailing Purdue’s “I Got My Life Back” video promotion that 
“followed six people who suffered from chronic pain and were treated with OxyContin”).
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“There’s no question that our best, strongest pain medicines are the opi-
oids . . . in fact, the rate of addiction amongst pain patients who are treated 
by doctors is much less than one percent.”16 In 2017, Dr. Jick lamented, “I’m
essentially mortified that that letter to the editor was used as an excuse to do 
what these drug companies did.”17
Exactly what these drug companies did is now the subject of litigation.18
And unlike previous public health courtroom battles, such as the tobacco lit-
igation of the 1990s, the prescription drugs at the heart of this deadly out-
break are heavily regulated for safety by the federal government.19 As a re-
sult, a diverse array of federal agencies have prioritized responding to the 
emergency.20 To understand why, consider the extent of the damage: the 
16. Our Amazing World, Purdue Pharma OxyContin Commercial, YouTube (Sept. 22, 
2016), https://www.youtube.com/watch?v=Er78Dj5hyeI [https://perma.cc/RZS9-9EVH]. In 
2007, the federal government brought criminal and civil charges against Purdue for the mis-
branding of OxyContin. Three top executives pleaded guilty to criminal charges, and the com-
pany paid $600 million in damages to the government and a class of private plaintiffs. Barry 
Meier, In Guilty Plea, OxyContin Maker to Pay $600 Million, N.Y. Times (May 10, 2007), 
https://www.nytimes.com/2007/05/10/business/11drug-web.html (on file with the Michigan 
Law Review). The privately held, family-owned company generated billions of dollars in annu-
al OxyContin sales, including as much as $3.1 billion in 2010. See Art Van Zee, The Promotion 
and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy, 99 Am. J. Pub. 
Health 221, 223 (2009); Mike Mariani, How the American Opiate Epidemic Was Started by 
One Pharmaceutical Company, Week (Mar. 4, 2015), http://theweek.com/articles/541564/how-
american-opiate-epidemic-started-by-pharmaceutical-company [https://perma.cc/3RNW-
2E2V].
17. Marilynn Marchione, Painful Words: How a 1980 Letter Fueled the Opioid Epidemic,
Associated Press (May 31, 2017), https://apnews.com/9307eb6e8b3c4970bb2a6344a09b0170
[https://perma.cc/23M3-BMX2].
18. Jerry Mitchell, Opioid Makers Face Hundreds of Lawsuits for Misleading Doctors 
About Drug’s Addictive Nature, USA Today (Jan. 29, 2018, 6:00 AM), https://
www.usatoday.com/story/news/nation-now/2018/01/29/judge-stop-legal-fights-and-curb-
opioid-epidemic/1072798001/ [https://perma.cc/8UVV-AM47].
19. Brian Eckert, This Is How Opioid Lawsuits Differ from Big Tobacco’s, Clas-
sAction.com (Jan. 19, 2018), https://www.classaction.com/news/opioid-lawsuits-big-tobacco/
[https://perma.cc/Q3DA-GCUS] (distinguishing between the opioids and tobacco litigation 
because “unlike tobacco, opioid painkillers were approved by the U.S. Food and Drug Admin-
istration”). During the 1990s tobacco litigation, the industry was still largely exempt from fed-
eral health and safety regulation. Tobacco Control Legal Consortium, Federal Regula-
tion of Tobacco 2 (2009), http://www.publichealthlawcenter.org/sites/default/files/resources/
tclc-fda-summary.pdf [https://perma.cc/4B34-DS2A] (noting that before the passage of the 
Family Smoking Prevention and Tobacco Control Act of 2009, “tobacco products were largely 
exempt from regulation under the nation’s federal health and safety laws”).
20. See, e.g., The Federal Response to the Opioid Crisis: Hearing Before the S. Comm. on 
Health, Educ., Labor &Pensions, 115th Cong. 2 (2017) (written testimony of Elinore McCance-
Katz, Assistant Sec’y for Mental Health & Substance Abuse, Substance Abuse & Mental Health 
Servs. Admin. et al. on behalf of the Dep’t of Health and Human Servs.) (describing the De-
partment of Health and Human Services’ “five-point Opioid Strategy”) [hereinafter McCance-
Katz Testimony]; Press Release: CDC Awards $28.6 Million to Help States Fight Opioid Over-
dose Epidemic Centers for Disease Control & Prevention, (Sept. 5, 2017), https://
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Substance Abuse and Mental Health Services Administration’s annual sur-
vey found that “over 11 million Americans misused prescription opioids”
and “2.1 million had an opioid use disorder due to prescription opioids or 
heroin” in 2016.21 Drug overdose deaths in 2016 totaled 63,000, which (after 
adjusting for age) represents a 21 percent increase over the prior year.22 This 
is “the largest annual jump ever recorded in the United States,” reaching a 
total greater than any peak number of annual deaths caused by car crashes, 
HIV, or guns throughout history.23 Opioids are responsible for 66 percent of 
those overdose deaths, killing more Americans annually than breast cancer.24
And 2017 estimates show those numbers rising across all races and nearly all 
age groups.25 In 2017, Stanford Professor of Psychiatry Keith Humphreys 
compared “the amount of standard daily doses of opioids consumed in Ja-
pan”—a nation with an “older population than us, you would think more 
aches and pains”—to that of the United States by saying, “double it. And 
then double it again. And then double it again. And then double it again. 
And then double it a fifth time. That would make Japan number two in the 
world behind the United States.”26 According to one forecast, opioids could 
kill 500,000 Americans over the next ten years.27
Dire as they are, the nationwide numbers mask the extent of the damage 
in the most heavily impacted localities. The highest-prescribed state sees 
three times as many opioid prescriptions per person as the lowest-prescribed 
state, despite “[h]ealth issues that cause people pain . . . not vary[ing] much 
www.cdc.gov/media/releases/2017/p0905-opioid-funding.html [https://perma.cc/9ZQJ-NQ3Z] 
(announcing CDC funding for states to “strengthen prevention efforts and better track opioid-
related overdoses”); DEA 360 Strategy, Drug Enforcement Admin., https://www.dea.gov/
prevention/360-strategy/360-strategy.shtml [https://perma.cc/8GPJ-HM6N] (describing the 
“DEA 360 Strategy,” an “innovative three-pronged approach to combating heroin/opioid 
use”).
21. McCance-Katz Testimony, supra note 20, at 2.
22. Holly Hedegaard et al., Ctrs. for Disease Control & Prevention, Drug 
Overdose Deaths in the United States, 1999–2016, at 1 (2017), https://www.cdc.gov/nchs/
data/databriefs/db294.pdf [https://perma.cc/YRN7-F8JT].
23. Josh Katz, Drug Deaths in America Are Rising Faster Than Ever, N.Y. Times: The 
Upshot (June 5, 2017), https://www.nytimes.com/interactive/2017/06/05/upshot/opioid-
epidemic-drug-overdose-deaths-are-rising-faster-than-ever.html (on file with the Michigan 
Law Review).
24. Nadia Kounang, Opioids Now Kill More People Than Breast Cancer, CNN (Dec. 21, 
2017, 12:14 AM), http://www.cnn.com/2017/12/21/health/drug-overdoses-2016-final-
numbers/ [https://perma.cc/9UTC-USVP].
25. Opioid Overdose: Data Overview, Ctrs. for Disease Control & Prevention,
https://www.cdc.gov/drugoverdose/data/index.html [https://perma.cc/N7F9-JPPC].
26. Stanford University (@Stanford), TWITTER (Sept. 16, 2017, 2:29 PM), https://
twitter.com/stanford/status/909167301349593094 [https://perma.cc/2XKT-4MWY] (showing 
Dr. Humphreys speaking at the 2017 Medicine X Conference).
27. Max Blau, STAT Forecast: Opioids Could Kill Nearly 500,000 Americans in the Next 
Decade, STAT (June 27, 2017), https://www.statnews.com/2017/06/27/opioid-deaths-forecast/
[https://perma.cc/C5DV-6XR7] (basing the estimate on an expert panel of public health re-
searchers and including a model of the data and possible outcomes in the article).
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from place to place.”28 Between 2007 and 2012, drug wholesalers shipped 780 
million pills of just hydrocodone and oxycodone to West Virginia.29 In Ker-
mit, West Virginia, a town of 392, drug companies shipped nearly nine mil-
lion pills of hydrocodone to a single pharmacy.30 In 2016, Montgomery 
County, Ohio saw a record 349 opioid deaths, but local officials estimate that 
2017 deaths could surpass 800.31 County coroners are overwhelmed by the
influx and struggling to find the physical space necessary to store bodies and 
conduct autopsies; some coroners have resorted to the use of refrigerated 
trailers.32 In New Hampshire, the backlog of autopsies is putting the state 
medical examiner’s office “at risk of losing accreditation.”33 That state has 
seen a nearly tenfold increase in overdose deaths since 2000.34
This human cost, in lost life and welfare, translates to a gargantuan toll 
on the economy. A 2017 study estimated the societal cost (including lost 
productivity, healthcare expenses, criminal justice costs, etc.) of the Opioid 
Epidemic at over $95 billion for 2016 alone.35 The White House Council of 
Economic Advisers, additionally placing a value on the loss of human life, 
estimated the 2015 cost of the crisis at over $500 billion, or 2.8 percent of 
GDP.36 These calculations do not incorporate the further costs of patients 
28. Opioid Overdose: Prescribing Data, CTRS. FOR DISEASE CONTROL & PREVENTION,
https://www.cdc.gov/drugoverdose/data/prescribing.html [https://perma.cc/49Y4-B6L8].
29. Eric Eyre, Drug Firms Poured 780M Painkillers into WV amid Rise of Overdoses,
CHARLESTON GAZETTE-MAIL (Dec. 17, 2016), https://www.wvgazettemail.com/news/
cops_and_courts/drug-firms-poured-m-painkillers-into-wv-amid-rise-of/article_99026dad-
8ed5-5075-90fa-adb906a36214.html [https://perma.cc/3FCX-4A62]. The state has a population 
under 2 million. Quick Facts: West Virginia, U.S. CENSUS BUREAU, https://www.census.gov/
quickfacts/WV [https://perma.cc/Z5Z3-VVU8]. Over that same period, 1,728 West Virginians 
died of overdoses on those two medications. Eyre, supra.
30. Eyre, supra note 29.
31. Poppy Harlow & Zach Wasser, Here, Heroin Spares No One, Not Even the Sheriff’s
Wife, CNN (Aug. 8, 2017), http://www.cnn.com/2017/08/06/health/ohio-heroin-opioid-crisis-
morgue-full/ [https://perma.cc/EMM9-YSKE].
32. See Ohio Coroner Runs Out of Room for Bodies Due to Spike in Opioid Deaths, CBS
NEWS (May 23, 2017, 2:40 PM), https://www.cbsnews.com/news/ohio-coroner-runs-out-of-
room-for-bodies-spike-in-opioid-deaths/ [https://perma.cc/WK6T-XGAA]; Corky Siemaszko, 
Too Many Bodies in Ohio Morgue, so Coroner Gets Death Trailer, NBC NEWS (Mar. 14, 2017, 
4:00 PM), https://www.nbcnews.com/news/us-news/too-many-bodies-ohio-morgue-so-
coroner-gets-death-trailer-n733446 [https://perma.cc/Z2HS-PLZU].
33. Katharine Q. Seelye, As Overdose Deaths Pile Up, a Medical Examiner Quits the 
Morgue, N.Y. TIMES (Oct. 7, 2017), https://www.nytimes.com/2017/10/07/us/drug-overdose-
medical-examiner.html (on file with the Michigan Law Review).
34. Id.
35. See CORWIN N. RHYAN, THE POTENTIAL SOCIETAL BENEFIT OF ELIMINATING 
OPIOID OVERDOSES, DEATHS, AND SUBSTANCE USE DISORDERS EXCEEDS $95 BILLION PER 
YEAR (2017), https://altarum.org/sites/default/files/uploaded-publication-files/Research-
Brief_Opioid-Epidemic-Economic-Burden.pdf [https://perma.cc/LE63-L5BX].
36. THE COUNCIL OF ECON. ADVISERS, THE UNDERESTIMATED COST OF THE OPIOID 
CRISIS 1 (2017), https://www.whitehouse.gov/sites/whitehouse.gov/files/images/The%20
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“initiated” into opioid addiction by prescription medications who then tran-
sition to cheaper, more widely available black-market heroin.37 The damage 
is sizable enough to cause macroeconomic impact: economists from Prince-
ton University, Goldman Sachs, and the Federal Reserve postulate that the 
perplexing decline in the labor participation rate is linked to opioids.38
This unprecedented rate of addiction and death amounts to the largest 
drug-related public health emergency in American history.39 Six states and 
the White House have declared official emergencies.40 And, because these 
drugs are FDA-approved medicines with legitimate applications, the chal-
lenge is distinct from past epidemics like the rise of heroin or crack cocaine. 
According to Scott Gottlieb, the commissioner of the FDA, “Most people 
who become addicted to opioids become medically addicted. Their first ex-
posure is going to be a clinical prescription that they receive in a clinical set-
ting, and then they’ll go on to develop an addiction.”41 Indeed, “many public 
health experts have traced the roots of the current surge in opioid addic-
Underestimated%20Cost%20of%20the%20Opioid%20Crisis.pdf [https://perma.cc/L4Q5-
Q6TU].
37. Prescription Opioid Use Is a Risk Factor for Heroin Use, NAT’L INST. ON DRUG ABUSE
(Jan. 2018), https://www.drugabuse.gov/publications/research-reports/relationship-between-
prescription-drug-heroin-abuse/prescription-opioid-use-risk-factor-heroin-use [https://
perma.cc/QW6B-V92J].
38. Alan B. Krueger, Where Have All the Workers Gone? An Inquiry into the Decline of 
the U.S. Labor Force Participation Rate, BROOKINGS PAPERS ON ECON. ACTIVITY, Fall 2017, at 
1, 1 (“[P]articipation has fallen more in areas where relatively more opioid pain medication is 
prescribed, causing the problem of depressed labor force participation and the opioid crisis to 
become intertwined.”); Mamta Badkar, Yellen: Opioid Crisis Weighing on US Labour Force Par-
ticipation, FIN. TIMES (July 13, 2017), https://www.ft.com/content/776ba9e3-d47c-3554-8421-
9238f79ef1b7 (on file with the Michigan Law Review); Danielle Paquette, The Stunning Preva-
lence of Painkiller Use Among Unemployed Men, WASH. POST: WONKBLOG (Sept. 7, 2017), 
https://www.washingtonpost.com/news/wonk/wp/2017/09/07/the-stunning-prevalence-of-
painkiller-use-among-unemployed-men/ [https://perma.cc/2446-9CBY]; Jeanna Smialek, 
Goldman Economists See Drug Epidemic Taking Toll on U.S. Economy, BLOOMBERG (July 6, 
2017, 4:52 PM), https://www.bloomberg.com/news/articles/2017-07-06/goldman-economists-
see-drug-epidemic-taking-toll-on-u-s-economy [https://perma.cc/4RQN-Y7Y3].
39. German Lopez & Sarah Frostenson, How the Opioid Epidemic Became America’s
Worst Drug Crisis Ever, in 15 Maps and Charts, VOX (Mar. 29, 2017, 12:51 PM), https://
www.vox.com/science-and-health/2017/3/23/14987892/opioid-heroin-epidemic-charts
[https://perma.cc/9SSP-BAX2].
40. Erin Mershon & Andrew Joseph, These States Declared an Emergency Over the Opi-
oid Crisis, Here’s What Happened, PBS (Aug. 10, 2017, 10:02 AM), https://www.pbs.org/
newshour/health/states-declared-emergency-opioid-crisis-heres-happened [https://perma.cc/
JN48-7TD4]; President Donald J. Trump Is Taking Action on Drug Addiction and the Opioid 
Crisis, WHITE HOUSE (Oct. 26, 2017), https://www.whitehouse.gov/the-press-office/2017/10/
26/president-donald-j-trump-taking-action-drug-addiction-and-opioid-crisis [https://perma.
cc/9E73-YVGK].
41. FDA’s Scott Gottlieb: Opioid Addiction is FDA’s Biggest Crisis Now, CNBC (July 21, 
2017, 8:24 AM), https://www.cnbc.com/video/2017/07/21/fdas-scott-gottlieb-opioid-
addiction-is-fdas-biggest-crisis-now.html [https://perma.cc/RAS7-2BPG].
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tion . . . to . . . prescription drugs”42 because “[t]he misuse of prescription 
opioids is intertwined with that of illicit opioids.”43 Four out of five new her-
oin users began by misusing a prescription opioid.44 Between 1996 and 1997, 
retail sales of hydrocodone increased by 244%, oxycodone by 732%, and 
methadone by 1,177%, coinciding with the trend of “increased rates of abuse 
and mortality associated with prescription opioid[s].”45 Thus, understanding 
the FDA scheme that regulates the prescription drugs in question is crucial.
This Note argues that the FDA’s administrative design misallocates the 
costs of the Opioid Epidemic and fails to adequately compensate those in-
jured by it. The FDA’s regulatory framework emphasizes premarket scrutiny 
but largely relies on state common law liability to police the postapproval 
drug market. As the Supreme Court increasingly holds state tort law 
preempted by federal administrative standards, the FDA’s framework be-
comes increasingly imbalanced. In the face of a historic prescription-
medication overdose crisis, the FDA’s scheme allows the pharmaceutical in-
dustry to avoid internalizing the dramatic public health costs of their opioid 
products. Part I summarizes the FDA’s regulatory framework with respect to 
opioid medications. Part II explains how that framework creates a compen-
satory problem that prevents the internalization of negative externalities by 
pharmaceutical manufacturers. Part III proposes a victims’ compensation 
fund as the best substitute for the function long performed by state tort lia-
bility.
I. The FDA’s “Floor/Ceiling” Scheme and the Preemption Lever
A. The FDA’s Administrative Design
Prescription drugs are regulated under the Food, Drug, and Cosmetics 
Act (FDCA), passed by Congress in 1938.46 The FDCA “imposes an elabo-
rate system” requiring premarket approval of new drugs following “extensive 
42. How Are Public Health Officials Fighting the Crisis of Opioid Addiction?, U. NEV.
RENO, https://onlinedegrees.unr.edu/blog/how-are-public-health-officials-fighting-the-crisis-
of-opioid-addiction/ [https://perma.cc/KCT4-84YJ].
43. Rose A. Rudd et al., Increases in Drug and Opioid-Involved Overdose Deaths—United 
States, 2010-2015, 65 MORBIDITY & MORTALITY WKLY. REP. 1445, 1450 (2016).
44. AM. SOC’Y OF ADDICTION MED., OPIOID ADDICTION 2016 FACTS & FIGURES (2016),
https://www.asam.org/docs/default-source/advocacy/opioid-addiction-disease-facts-figures.
pdf [https://perma.cc/B56H-88DQ].
45. Kathryn L. Hahn, Strategies to Prevent Opioid Misuse, Abuse, and Diversion That 
May Also Reduce the Associated Costs, 4 AM. HEALTH & DRUG BENEFITS 107, 108–09 (2011).
46. How Did the Federal Food, Drug, and Cosmetic Act Come About?, U.S. FOOD &
DRUG ADMIN., https://www.fda.gov/AboutFDA/Transparency/Basics/ucm214416.htm
[https://perma.cc/E35H-RFY2].
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testing and stringent risk/benefit analysis.”47 The approval process is notori-
ously onerous.48 The process requires every manufacturer to submit a “New 
Drug Application” showing data from multiple phases of animal and human 
preclinical and clinical testing as well as results from a variety of other forms 
of research and investigation.49 The burden is on the manufacturer to show 
by substantial evidence that its drug meets the standard of “safe and effec-
tive” under the conditions recommended for its use.50 Because all drugs have 
“potential risks, contraindications, . . . and adverse reactions,” the approval 
process also involves a rigorous labeling-approval process to ensure a drug’s
label “provides doctors information needed to make informed prescribing 
decisions.”51 The FDCA implements a “risk-benefit assessment framework”
to determine when a drug poses an acceptable degree of risk in light of its 
benefits.52
That risk–benefit analysis is central to the FDA’s regulatory scheme. 
Quantifying costs is especially challenging when an agency must analyze the 
risk of injury or death of human beings.53 But that is the FDA’s task every 
time it evaluates whether a new drug meets the “safe and effective” stand-
47. Catherine T. Struve, The FDA and the Tort System: Postmarketing Surveillance, 
Compensation, and the Role of Litigation, 5 YALE J. HEALTH POL’Y L. & ETHICS 587, 587 (2005).
See generally Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 351–60 (2012) (providing the 
premarket approval requirements for drugs and devices).
48. In President Trump’s first Joint Address to Congress, he noted that “our slow and 
burdensome approval process at the Food and Drug Administration keeps too many advanc-
es . . . from reaching those in need.” Remarks by President Trump in Joint Address to Congress,
WHITE HOUSE (Feb. 28, 2017), https://www.whitehouse.gov/the-press-office/2017/02/28/
remarks-president-trump-joint-address-congress [https://perma.cc/42UW-4NR9]; see also Big 
Pharma’s Gripes About the FDA, ECONOMIST (July 1, 2011), https://www.economist.com/
blogs/schumpeter/2011/07/cancer-drugs [https://perma.cc/KD2A-XGGV] (“Talk to anyone in 
the pharmaceutical industry . . . and within three minutes Mr. Pharma will start griping 
about . . . the FDA’s approval process . . . .”).
49. See 21 U.S.C. § 355 (2012); The FDA’s Drug Review Process: Ensuring Drugs Are Safe 
and Effective, U.S. FOOD & DRUG ADMIN. (Nov. 24, 2017), https://www.fda.gov/Drugs/
ResourcesForYou/Consumers/ucm143534.htm [https://perma.cc/4E3V-4YBF].
50. See § 355.
51. David C. Vladeck, Preemption and Regulatory Failure Risks, in PREEMPTION CHOICE
54, 65 (William W. Buzbee ed., 2009). See generally § 355 (establishing procedures for initial 
drug labeling and labeling revisions).
52. § 355; Marcia Boumil, FDA Approval of Drugs and Devices: Preemption of State 
Laws for “Parallel” Tort Claims, 18 J. HEALTH CARE L. & POL’Y 1, 4 (2015) (“The FDA employs 
a standard stating that the drugs’ ‘probable therapeutic benefits must outweigh its risk of 
harm.’ ”); JAMIE WILKINS PARKER, U.S. FOOD & DRUG ADMIN., RISK MANAGEMENT IN THE 
UNITED STATES (2013), https://www.fda.gov/downloads/drugs/resourcesforyou/
healthprofessionals/ucm473163.pdf [https://perma.cc/6GS4-HHQE]; U.S. FOOD & DRUG 
ADMIN., STRUCTURED APPROACH TO BENEFIT-RISK ASSESSMENT IN DRUG REGULATORY 
DECISION-MAKING (2013), https://www.fda.gov/downloads/forindustry/userfees/prescription
druguserfee/ucm329758.pdf [https://perma.cc/QZ6E-VDYB].
53. See Lewis A. Kornhauser, The Value of Life, 38 CLEV. ST. L. REV. 209 (1990). See gen-
erally GUIDO CALABRESI & PHILIP BOBBITT, TRAGIC CHOICES (1978).
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ard.54 A drug is never entirely risk free, so warning labels are crucial.55 An 
approved warning label informs doctors and patients about the risks they as-
sume in prescribing and taking a drug respectively.56 When a label is inaccu-
rate or incomplete, or when a drug is marketed for nonapproved uses, the 
manufacturer can face liability under the FDCA for “misbranding.”57 That 
potential penalty incentivizes manufacturers to update a drug’s warning la-
bel for risks that arise following approval using the “Changes Being Effected”
(CBE) process.58 The FDA primarily relies on manufacturers supplying in-
formation through the CBE process to detect postmarket risks.59 By the 
FDA’s own account, “[s]ignificant, but substantially fewer, resources are de-
voted to postmarketing surveillance and risk assessment activities” com-
pared to premarket approval.60
This raises the question of who bears the “costs” of a system built on 
cost-benefit analysis. The FDCA does not include any private right of action 
or other remedy for consumers injured by unforeseen risks.61 The Supreme 
Court interpreted this omission as Congress’s determination “that widely 
54. See TASK FORCE ON RISK MGMT., FOOD & DRUG ADMIN., MANAGING THE RISKS 
FROM MEDICAL PRODUCT USE 29–30 (1999) (“The Agency establishes and enforces product 
quality standards intended to prevent defective products from reaching the market . . . The 
majority of FDA program resources are devoted to premarketing scientific risk identification 
and assessment and approval or nonapproval.”).
55. Vladeck, supra note 51, at 65.
56. MARY E. KREMZNER & STEVEN F. OSBORNE, U.S. FOOD & DRUG ADMIN., AN
INTRODUCTION TO THE IMPROVED FDA PRESCRIPTION DRUG LABELING 50, https://www.fda.
gov/downloads/training/forhealthprofessionals/ucm090796.pdf [https://perma.cc/QV9Q-
B4XR].
57. See §§ 331(a), 333(a), 352(a); see also 21 C.F.R. § 201.1 (2017) (further defining 
“misbranded” under the FDCA).
58. See 21 U.S.C. § 356(a) (2012); 21 C.F.R. § 314.70 (2017); see also Stacey B. Lee, 
PLIVA v. Mensing: Generic Consumers’ Unfortunate Hand, 12 YALE J. HEALTH POL’Y L. &
ETHICS 209, 242–43 (2012) (“The potential damage awards from state failure-to-warn litigation 
provides drug manufacturers with incentives to quickly provide full and clear information to 
physicians and the FDA that otherwise may not come to light.”); FOOD & DRUG ADMIN.,
GUIDANCE FOR INDUSTRY: CHANGES TO AN APPROVED NDA OR ANDA, https://www.fda.gov/
downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm077097.pdf
[https://perma.cc/JL9D-AC9T].
59. See Supplemental Applications Proposing Labeling Changes for Approved Drugs 
and Biological Products, 78 Fed. Reg. 67,985, 67,986–88 (Nov. 13, 2013) (to be codified at 21 
C.F.R. pts. 314, 601) (“Application holders also must comply with requirements for other 
postmarketing reports . . . . These requirements include submission of an annual report (in-
cluding a brief summary of significant new information from the previous year that might af-
fect the safety, effectiveness, or labeling of the drug product, and a description of actions the 
applicant has taken or intends to take as a result of this new information) and, if appropriate, 
proposed revisions to product labeling . . . .”); Lee, supra note 58, at 250–52.
60. TASK FORCE ON RISK MGMT., FOOD & DRUG ADMIN., supra note 54, at 29–30.
61. Wyeth v. Levine, 555 U.S. 555, 574 (2009) (“Congress did not provide a federal rem-
edy for consumers harmed by unsafe or ineffective drugs in the 1938 statute or in any subse-
quent amendment.”).
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available state rights of action provide[] appropriate relief for injured con-
sumers” in part because “state-law remedies further consumer protection by 
motivating manufacturers to produce safe and effective drugs and to give ad-
equate warnings.”62
The FDCA framework was therefore designed as a “floor” of oversight 
and regulation, where state common law liability provided the complemen-
tary “ceiling.” This model of regulation takes advantage of the layers of re-
dundant governance: “[T]he federal government sets a minimum required 
level of stringent protection, and states, local governments, and common law 
regimes can lead to even more protective results.”63 The preservation of state 
common law liability “creates ongoing private incentives to challenge the 
status quo,” a “particularly valuable antidote[] to complacency and ineffec-
tive regulation.”64 But when common law liability lurks in the background of 
an industry’s compliance with a complex federal scheme, regulated entities 
face increased uncertainty and expenditure.65 These competing interests of 
consumer protection and regulatory efficiency are balanced between the 
FDCA’s floor and ceiling.
B. The Role of Preemption and the Shifting Balance
The constitutional doctrine of preemption is a lever for optimizing this 
balance between consumer protection and regulatory efficiency. Preemption 
arises out of the Supremacy Clause.66 Because “federal law reigns supreme,”
it “preempts any conflicting law or law that federal legislation deems 
preempted.”67 Preemption can be “based on an express or implied legislative 
or regulatory determination.”68 Express preemption clauses speak for them-
selves, while implied preemption is broken into three main categories.69 The 
three categories of implied preemption are as follows: “Field” preemption, 
where the federal government intentionally or effectively has exclusive au-
thority to “occupy the field” alone (such as issues of foreign affairs);70 and 
62. Id.; see also id. at 567 (“As it enlarged the FDA’s powers to protect the public health 
and assure the safety, effectiveness, and reliability of drugs, Congress took care to preserve state 
law.” (citations omitted) (quoting Drug Amendments of 1962, Pub. L. No. 87-781, 76 Stat. 780, 
780)).
63. William W. Buzbee, Federal Floors, Ceilings, and the Benefits of Federalism’s Institu-
tional Diversity, in PREEMPTION CHOICE, supra note 51, at 104.
64. Id. at 114.
65. Additional expense and uncertainty result from the need for state-by-state analysis 
of variable common law tort standards and the injection of a jury’s judgment. See id.
66. U.S. CONST. art. VI, cl. 2.
67. William W. Buzbee, Introduction to PREEMPTION CHOICE, supra note 51, at 1.
68. Barbara L. Atwell, Products Liability and Preemption: A Judicial Framework, 39 
BUFF. L. REV. 181, 183 (1991).
69. Id. at 183–86.
70. See English v. Gen. Elec. Co., 496 U.S. 72, 79 (1990) (quoting Rice v. Santa Fe Eleva-
tor Corp., 331 U.S. 218, 230 (1947)) (noting that a field can be preempted when the federal 
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two kinds of “conflict” preemption: where complying with both state and 
federal law at once is “physically impossible” (such as a federal regulation 
imposing one standard that is directly at odds with a state standard);71 and 
where state law poses a sufficient “obstacle” to fulfilling Congress’s intent 
(such as a state imposing additional regulation in an interfering manner on 
top of existing federal requirements).72
In a floor/ceiling model, the degree to which federal standards preempt 
common law liability sets the height of the regulatory ceiling. As the con-
temporary administrative state expands, “it is not surprising that federal 
preemption has become an increasingly popular defense.”73 A regulated enti-
ty, such as a pharmaceutical manufacturer, might argue that its compliance 
with the FDCA regulatory framework preempts concurrent state common 
law liability.74 The FDCA’s regulation of drugs, however, includes no express 
preemption clause (unlike its section on medical devices).75 And for nearly 
all of the FDCA’s history, courts and the FDA did not take the position that 
multilayered pharmaceutical regulation amounted to an implied preemp-
tion.76
In recent years though, the FDA’s stance on preemption has shifted. In 
2006, without prior warning, the FDA “slipped a preemptive statement into 
regulatory scheme is “so pervasive as to make reasonable the inference that Congress left no 
room for the States to supplement it”). Field preemption can also apply to areas where the fed-
eral interest is dominant, regardless of the extent of regulation. See, e.g., Hines v. Davidowitz, 
312 U.S. 52, 62 (1941) (“[T]he supremacy of the national power in the general field of foreign 
affairs . . . is made clear by the Constitution.”).
71. See, e.g., Fla. Lime & Avocado Growers, Inc. v. Paul, 373 U.S. 132, 142–43 (1963) (“A
holding of federal exclusion of state law is inescapable . . . where compliance with both federal 
and state regulations is a physical impossibility for one engaged in interstate commerce.” (cita-
tions omitted)).
72. See, e.g., Arizona v. United States, 567 U.S. 387, 402–03 (2012) (holding that Arizona 
law authorizing police to inspect a person’s immigration status posed an obstacle to federal 
immigration law).
73. Atwell, supra note 68, at 181.
74. See W. Kip Viscusi et al., Deterring Inefficient Pharmaceutical Litigation: An Eco-
nomic Rationale for the FDA Regulatory Compliance Defense, 24 SETON HALL L. REV. 1437, 
1438 (1994) (“[T]ort liability is generally inappropriate in cases where manufacturers have 
complied with the FDCA.”).
75. John C.P. Goldberg & Benjamin C. Zipursky, The Supreme Court’s Stealth Return to 
the Common Law of Torts, 65 DEPAUL L. REV. 433, 451 (2016) (“To be sure, the FDCA, unlike 
the MDA, contained no express preemption provision.”).
76. See Wyeth v. Levine, 555 U.S. 555, 567 (2009) (“The 1962 amendments added a sav-
ing clause, indicating that a provision of state law would only be invalidated upon a ‘direct and 
positive conflict’ with the FDCA. Consistent with that provision, state common-law suits con-
tinued ‘unabated despite . . . FDA regulation.’ ” (citation omitted) (quoting Drug Amendments 
of 1962, Pub. L. No. 87-781, § 202, 76 Stat. 780, 793  (codified at 21 U.S.C. § 301 (2016)), and 
Riegel v. Medtronic, Inc., 552 U.S. 310, 340 (2008) (Ginsburg, J., dissenting))).
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the preamble of its rulemaking on the format of prescription drug labels.”77
The preamble stated a new interpretation of the FDA’s regulatory scheme as 
establishing both floor and ceiling, a dramatic departure from the FDCA’s
historical interpretation.78
Initially, the Supreme Court rebuffed this logic. In the 2009 landmark
case Wyeth v. Levine, the Court was not swayed by the FDA’s changed 
stance.79 In a decision hailed as “one of the most important Supreme Court 
victories for consumers in many years,”80 the Court rejected a pharmaceuti-
cal manufacturer’s impossibility preemption defense that argued the “FDCA 
establishes both a floor and a ceiling for drug regulation.”81 The Court held 
that a state law failure-to-warn claim against a brand-name pharmaceutical 
manufacturer, whose drug caused the plaintiff to lose an arm to gangrene, 
was not preempted by the FDA’s approval of the drug’s warning label.82 The 
Court reasoned that it was not “impossible” to comply with both federal and 
state standards because the manufacturer could update its warning label us-
ing the CBE process.83
The Supreme Court’s subsequent decisions, however, undermined Wy-
eth and embraced preemption of state law in most pharmaceutical litigation. 
In 2011 and 2013, the Court expanded impossibility preemption in PLIVA,
Inc. v. Mensing84 and in Mutual Pharmaceutical Co. v. Bartlett.85 Those cases 
involved generic drugs, as opposed to the brand-name drug at issue in Wy-
eth.86 In 2016, generic drugs accounted for nearly 90 percent of prescriptions 
dispensed.87 Under the FDCA, a generic drug manufacturer cannot unilater-
77. Nina A. Mendelson, A Presumption Against Agency Preemption, 102 NW. U. L. REV.
695, 703 (2008) (referring to Requirements on Content and Format of Labeling for Human 
Prescription Drug and Biological Products, 71 Fed. Reg. 3922, 3934 (Jan. 24, 2006) (codified at 
21 C.F.R. pts. 201, 314, 601 (2017))).
78. Requirements on Content and Format of Labeling for Human Prescription Drug 
and Biological Products, 71 Fed. Reg. at 3935.
79. 555 U.S. at 577 (“[T]he FDA’s 2006 preamble does not merit deference [because] the 
agency finalized the rule . . . without offering States or other interested parties notice or oppor-
tunity for comment, articulat[ing] a sweeping position on the FDCA’s pre-emptive effect[such 
that t]he agency’s views on state law are inherently suspect in light of this procedural failure.”).
80. Erwin Chemerinsky, Wyeth Is Victory for Consumers, Blow to Preemption, TRIAL,
May 2009, at 54, 54.
81. Wyeth, 555 U.S. at 573–74 (finding the argument inadequate because “all evidence 
of Congress’ purposes is to the contrary”).
82. Id. at 559, 581.
83. Id. at 570–71 (“[A]s amputations continued to occur, Wyeth could have analyzed 
the accumulating data and added a stronger warning . . . .”).
84. 564 U.S. 604 (2011) (plurality opinion in part).
85. 570 U.S. 472 (2013).
86. Bartlett, 570 U.S. at 475; Mensing, 564 U.S. at 609.
87. Proportion of Branded Versus Generic Drug Prescriptions Dispensed in the United
States from 2005 to 2016, STATISTA (May 2017), https://www.statista.com/statistics/205042/
proportion-of-brand-to-generic-prescriptions-dispensed/ (on file with the Michigan Law Re-
view).
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ally modify its drug’s composition or its warning label using the CBE pro-
cess, because of the “duty of ‘sameness,’ ” which requires the generic warning 
label to be identical to the brand-name label.88 Therefore, the Court held that 
subjecting a generic manufacturer to both the federal duty of sameness and 
state tort law liability for a design defect or inadequate warning label 
amounted to an “impossibility” conflict.89 The Court reached this conclusion 
despite the FDA’s objections.90 The agency argued that a generics manufac-
turer in this position could seek permission “to work toward strengthening 
the label that applies to both the generic and brand-name” drugs, rather than 
taking no action at all.91 Moreover, state law did not require the manufactur-
er to change the drug’s composition or modify its label if the manufacturer 
simply compensated the injured consumers.92 Prior to these cases, the “im-
possibility” category of preemption was reserved for physical impossibili-
ties.93 But here, the Court found impossibility in situations where only the 
avoidance of liability is impossible, a result that Justice Sotomayor character-
ized as “frankly astonishing.”94
The Supreme Court’s post-Wyeth pharmaceutical preemption decisions 
amount to a novel application of the doctrine with seismic social policy im-
plications.95 This line of cases immunizes most drug manufacturers from 
88. Mensing, 564 U.S. at 613 (“[T]he warning labels of a brand-name drug and its gener-
ic copy must always be the same—thus, generic drug manufacturers have an ongoing federal 
duty of ‘sameness.’ ”).
89. Bartlett, 570 U.S. at 480 (“In the instant case, it was impossible for Mutual to comply 
with both its state-law duty . . . and its federal-law duty . . . .”); Mensing, 564 U.S. at 618 (“We 
find impossibility here.”).
90. Mensing, 564 U.S. at 616.
91. Id.
92. Bartlett, 570 U.S. at 514 (Sotomayor, J., dissenting) (“New Hampshire, through its 
design-defect law, has made a judgment that some drugs . . . should . . . not be sold unless the 
manufacturer is willing to compensate injured consumers.”).
93. See Amici Curiae Brief of the Am. Ass’n for Justice & Pub. Justice in Support of Re-
spondent at 6, Bartlett, 570 U.S. 472 (No. 12-142) (“[Physical] ‘impossibility’ can only exist 
when two statutes impose ‘directly conflicting duties’—’as they would, for example, if the fed-
eral law said, “you must sell insurance,” while the state law said, “you may not.” ’ But ‘physical 
impossibility’ does not exist where state law merely authorizes an action that federal law for-
bids.” (citations omitted) (quoting Barnett Bank of Marion Cty., N.A. v. Nelson, 517 U.S. 25, 
31 (1996))).
94. Bartlett, 570 U.S. at 514–18 (Sotomayor, J., dissenting) (“[T]he majority . . . finds 
impossibility where it does not exist by relying on a question-begging assumption that Con-
gress intended for Mutual to have a way to continue selling sulindac without incurring com-
mon-law liability.”).
95. See Brian Wolfman & Anne King, Mutual Pharmaceutical Co. v. Bartlett and Its Im-
plications, 82 U.S.L. WK. 667, 669 (2013) (“Whatever one thinks of the Supreme Court’s legal 
analyses in Wyeth, PLIVA, and Mutual, the results of those decisions, taken together, make 
nonsensical public policy.”).
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state common law liability.96 Under this regime, when two plaintiffs suffer 
the same injury from a defective brand-name drug and its generic equiva-
lent, only the former has a claim against the manufacturer.97 Even the Court 
acknowledged this outcome “makes little sense” for pharmaceutical consum-
ers,98 and commentators found the decisions “bizarre.”99 To the pharmaceu-
tical industry, the decisions signaled an increasing preference by the Court 
for immunizing manufacturers from state common law liability.100 In the 
face of the Opioid Epidemic, the Supreme Court has severely obstructed a 
major pathway to remedying consumer injuries and penalizing manufactur-
ers.
II. The Supreme Court’s New Step in Preemption’s Doctrinal 
Thicket Creates a Compensation Problem
By expanding the concept of impossibility preemption, the Supreme 
Court reduced the essential role of state common law in the FDA’s adminis-
trative design. This prevents internalization of prescription opioids’ external-
ities and compensation for the injured. The Court’s increasing preference for 
centralized, standard-setting regulation over localized, market-based com-
pensatory torts shelters industry at the expense of consumers. Section II.A 
contends that the Court’s novel preemption analysis marginalizes the tort 
system’s essential role in the FDA’s administrative design. Section II.B ar-
gues that the remaining federal regulatory scheme is inadequate on its own. 
Section II.C acknowledges that, even at the proper floor/ceiling balance, torts 
alone cannot compensate all victims of the Opioid Epidemic.
96. See id. (stating that the vast majority of prescriptions are for generics, such that “the 
upshot of Mutual and PLIVA is that most people harmed by prescription generic drugs have 
lost their access to the courts”).
97. Id. (“An injured consumer’s ability to recover for her injuries from a culpable drug 
manufacturer depends . . . ‘on the happenstance’ of whether the consumer’s pharmacist dis-
pensed the brand-name or generic version of the drug.” (quoting PLIVA, Inc. v. Mensing, 564 
U.S. 604, 627 (2011) (Sotomayor, J., dissenting))).
98. Mensing, 564 U.S. at 625.
99. Opinion, A Bizarre Outcome on Generic Drugs, N.Y. TIMES (Mar. 23, 2012) http://
www.nytimes.com/2012/03/24/opinion/a-bizarre-outcome-on-generic-drugs.html (on file 
with the Michigan Law Review); see also Erwin Chemerinsky, Opinion, Justice for Big Business,
N.Y. TIMES (July 1, 2013), http://www.nytimes.com/2013/07/02/opinion/justice-for-big-
business.html (on file with the Michigan Law Review) (characterizing the decisions as part of a 
trend wherein the Court “closed the courthouse doors to employees, consumers and small 
businesses seeking remedy for serious injuries”).
100. See, e.g., James M. Beck, Bartlett—A Big Win for Preemption, DRUG & DEVICE L.
(June 24, 2013), https://www.druganddevicelawblog.com/2013/06/bartlett-big-win-for-
preemption.html [https://perma.cc/84UU-LKV4]; James M. Beck, Ruminations on Independ-
ence and Inaction: Further Implications of Bartlett, DRUG & DEVICE L. (July 3, 2013), https://
www.druganddevicelawblog.com/2013/07/ruminations-on-independence-and.html [https://
perma.cc/8KAT-MC42].
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A. The Court’s Embrace of Preemption Minimizes the Crucial Role of Torts
The Supreme Court’s preemption cases displace the economic functions 
traditionally performed by the state tort system. After Mensing and Bartlett,
manufacturers of generic drugs are “effectively immunized” from products 
liability schemes.101 Given that nearly 90 percent of prescriptions are for ge-
neric drugs,102 this leaves the vast majority of injured patients without a path 
to economic recovery. Tort liability incentivizes manufacturers to avoid lia-
bility by policing their drugs for adverse effects postapproval103 and then 
compensates the victims effectively.104 By embracing preemption, the Court 
has replaced the internalization and compensation that torts provide with 
the model codes of conduct of the federal administrative state.105
The federal regulatory scheme alone cannot perform the same economic 
functions as parallel tort regulation. Federal regulation “replace[s] the ex 
post, decentralized form of private regulation” that torts provide “with ex 
ante, centralized public administrative rules.”106 Because that ex ante deter-
mination is premised on a risk–benefit analysis,107 the injuries that do still 
occur need to be compensated. The FDA, though, does not compensate the 
victims of its cost-benefit analyses.108 Pharmaceutical companies should fill 
101. Goldberg & Zipursky, supra note 75, at 454.
102. QUINTILES IMS INST., MEDICINES USE AND SPENDING IN THE U.S. 43 (2017), https://
structurecms-staging-psyclone.netdna-ssl.com/client_assets/dwonk/media/attachments/590c/
6aa0/6970/2d2d/4182/0000/590c6aa069702d2d41820000.pdf?1493985952 [https://perma.cc/
S6EC-FVEA].
103. Tyler W. Olson, Note, The Supreme Court’s Overreaching Preemption Interpretation 
and Its Consequences: Granting Generic Drug Manufacturers Legal Immunity Through “the Du-
ty of Sameness” in Mutual Pharmaceutical Co. v. Bartlett and PLIVA v. Mensing, 12 IND.
HEALTH L. REV. 769, 771 (2015).
104. See Sprietsma v. Mercury Marine, 537 U.S. 51, 64 (2002) (explaining that “unlike 
most administrative and legislative regulations,” common-law claims “necessarily perform an 
important remedial role in compensating accident victims”); Struve, supra note 47, at 590 
(“Empirical data indicate that juries do better than their critics assert at handling technical is-
sues, that juries are not as eager as some think to award damages against business defendants, 
and that punitive damages are awarded rarely in products liability suits. . . .” (footnotes omit-
ted)).
105. See Goldberg & Zipursky, supra note 75, at 454 (“[A] judge or jury in a particular 
tort case. . . [finding] the defendant breached a duty of care by injuring the plaintiff is quite 
distinct from a state legislature or regulatory body declaring that certain conduct is prohibited 
or required,” just as “a state’s maintenance of laws, through which an actor can be held liable to 
provide redress to an injury-victim . . . is a far cry from state regulation.”).
106. See Catharine M. Sharkey, The Administrative State and the Common Law: Regula-
tory Substitutes or Complements?, 65 EMORY L.J. 1705, 1710 (2016).
107. See U.S. GEN. ACCOUNTING OFFICE, FDA DRUG REVIEW: POST APPROVAL RISKS 
1976-1985, at 2–3 (1990), http://archive.gao.gov/d24t8/141456.pdf [https://perma.cc/M2S9-
NUMZ] (finding that between 1976 and 1985, 51 percent of FDA-approved drugs had serious 
unforeseen postapproval risks).
108. See Mut. Pharm. Co. v. Bartlett, 570 U.S. 472, 500 (2013) (Sotomayor, J., dissenting) 
(“Perhaps most significant, state common law provides injured consumers like Karen Bartlett 
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that role, as the FDCA imagined, given they are likely the cheapest cost 
avoider.109 Drug manufacturers “are better able to control product safety”
and “possess superior capacity for risk distribution.”110 Drug consumers, by 
contrast, are patients following the instructions of a doctor, and pharmaceu-
tical companies “cultivate and profit from consumer reliance on the safety”
of their drugs.111 That is why the strict-liability common law tort scheme 
preempted in Bartlett was an essential element in the federal regulatory de-
sign.112 Without that compensatory safety net, the manufacturer does not 
internalize the costs of a drug’s harms, and consumers bear the burden. As 
Judge Calabresi put it, “the pharmaceutical industry’s drive for federal 
preemption would have the effect of imposing direct, centralized, and high-
level decisions as to the value of life and limb” on the FDA approval pro-
cess.113 Under the FDCA’s intended design, “the costs of tort law are . . .
borne by the drug companies,” but when preemption is applied “costs . . .
would be borne, pretty much entirely, by people other than those compa-
nies.”114 Thus, “[w]ho can doubt that the pharmaceutical companies have, to 
this extent, an important distributional reason to push for preemption and 
regulation[?]”115
The pharmaceutical industry may argue that the FDA’s standards are 
sufficient, but the role of the torts “ceiling” in the FDCA framework is cru-
cial. Despite the FDA’s valuable expertise regarding drug safety and approv-
al,116 “safety issues plague FDA-approved drugs that remain on the market, 
as more than 100,000 consumers are killed every year as a consequence of 
with an opportunity to seek redress that is not available under federal law.”); Robert L. Rabin, 
Keynote Paper: Reassessing Regulatory Compliance, 88 GEO. L.J. 2049, 2073 (2000) (“Regulatory 
agencies are not in the business of compensating for accidental harm arising from activities 
within the ambit of their authority.”); see also CASS R. SUNSTEIN, THE COST–BENEFIT STATE 
55–68 (2002) (discussing how federal agencies regulate via standard setting based on cost/
benefit analyses).
109. See Guido Calabresi & Jon T. Hirschoff, Toward a Test for Strict Liability in Torts, 81 
YALE L.J. 1055, 1062 (1972) (“The producer is in a position to compare the existing accident 
costs with the costs of avoiding this type of accident by developing either a new product or a 
test which would serve to identify the risky .0001 per cent. The consumer, in practice, cannot 
make this comparison. Relatively, the producer is the cheapest cost avoider, the party best suit-
ed to make the cost-benefit analysis and to act upon it.”); Olson, supra note 103, at 780–81.
110. MARK C. RAHDERT, COVERING ACCIDENT COSTS 90 (1995).
111. Id.
112. See Bartlett, 570 U.S. at 514 (Sotomayor, J., dissenting) (“Not all products can be 
made safe for sale with an improved warning or a tweak in design. New Hampshire, through 
its design-defect law, has made a judgment that some drugs that were initially approved for 
distribution turn out to be inherently and unreasonably dangerous and should therefore not be 
sold unless the manufacturer is willing to compensate injured consumers.”).
113. GUIDO CALABRESI, THE FUTURE OF LAW & ECONOMICS 37–38 (2016) (endnote 
omitted).
114. Id. at 39.
115. Id.
116. See, e.g., Struve, supra note 47, at 591 (“[T]he FDA’s expertise gives its views on 
product safety considerable authority. . . .”).
160 Michigan Law Review [Vol. 117:143
medical devices and pharmaceutical use.”117 The FDA’s inadequacy in this 
domain is well established.118 It is itself evidence of Congress’s “understand-
ing of the limitations of ex ante federal regulatory review” and “preservation 
of a role for state law generally, and common-law remedies specifically.”119
The FDA does not independently conduct safety testing when considering 
approval applications but rather relies upon the manufacturers.120 Nor does 
the FDA independently monitor for serious risks which arise postapproval121
(though it is aware that such problems will arise).122 The FDA instead relies 
on manufacturers’ self-reporting.123 While the FDA has a variety of en-
forcement tools for policing its postapproval jurisdiction,124 those mecha-
nisms cannot effectively monitor the entire market.125 Without the specter of 
common law liability, manufacturers have little incentive to perform these 
information-generating functions.
117. Boumil, supra note 52, at 6; see also Bartlett, 570 U.S. at 500 (Sotomayor, J., dissent-
ing) (“On its own, even rigorous preapproval clinical testing of drugs is generally . . . incapable 
of detecting adverse effects that occur infrequently, have long latency periods, or affect sub-
populations not included or adequately represented in the studies.” (quoting David A. Kessler 
& David C. Vladeck, A Critical Examination of the FDA’s Efforts to Preempt Failure-to-Warn 
Claims, 96 GEO. L.J. 461, 471 (2008))).
118. See, e.g., INST. OF MED. OF THE NAT’L ACADS., THE FUTURE OF DRUG SAFETY 4
(2007), https://www.nap.edu/read/11750/chapter/1 [https://perma.cc/B4T5-YSEV] (consider-
ing the FDA’s drug safety monitoring system, and finding that “FDA . . . and the pharmaceuti-
cal industry . . . do not consistently demonstrate accountability and transparency”).
119. See Bartlett, 570 U.S. at 500 (Sotomayor, J., dissenting).
120. See 21 U.S.C. § 355(b) (2012) (prescribing the FDCA’s filing requirements for new 
drugs); Rabin, supra note 108, at 2069 (“Even in the case of a comprehensive regulatory regime 
like FDA certification of new drugs . . . the burden is on the company to produce evidence in 
support of its new drug application, and the agency does not conduct its own testing and ex-
perimentation.” (footnotes omitted)).
121. See Bartlett, 570 U.S. at 500 (Sotomayor, J., dissenting) (“[T]he FDA, which is tasked 
with monitoring thousands of drugs on the market and considering new drug applications, 
faces significant resource constraints that limit its ability to protect the public from dangerous 
drugs.”).
122. See Rabin, supra note 108, at 2077 (“[P]rescription drugs have a dynamic and often 
unpredictable life after regulatory approval” that is “intrinsic to both . . . the nature of the 
product and the process by which it is approved.”).
123. See 21 C.F.R. § 314.80 (2017) (requiring for the “postmarketing reporting of adverse 
drug experiences”).
124. See Guidance, Compliance, & Regulatory Information, U.S. FOOD & DRUG ADMIN.
https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/default.htm [https://
perma.cc/5TK3-H34Y]; Step 5: FDA Post-Market Drug Safety Monitoring, U.S. FOOD & DRUG 
ADMIN., https://www.fda.gov/ForPatients/Approvals/Drugs/ucm405579.htm [https://
perma.cc/H5KU-H7M4].
125. See Struve, supra note 47, at 601 (citing an internal FDA survey finding “two-thirds 
of respondents” were less than fully confident that FDA “adequately monitors the safety of pre-
scription drugs once they are on the market,” and stating that “[t]he FDA receives large 
amounts of data . . . from regulated companies” that “will sometimes be incomplete or lack 
sufficient detail”).
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B. An Inadequate Regulatory Scheme Remains Post-Preemption
The Opioid Epidemic presents a prime example of the compensatory 
problem that results from a lack of incentive to monitor the safety of ap-
proved drugs. Though the degree to which the manufacturers of opioids are 
responsible for the addiction crisis remains uncertain,126 existing evidence 
indicates a significant contribution.127 That evidence has led to an onslaught 
of litigation against the major opioids manufacturers and distributors.128 So 
far, several state attorneys general, over sixty counties and municipalities, the 
Cherokee Nation, multiple labor unions, and private classes of plaintiffs have 
brought actions.129 The dozens of lawsuits bring varied theories of liability, 
but they “generally allege the drug companies downplayed the addictive risks 
of the drugs in order to turn a profit.”130 The defendants raise preemption in 
response.131
The lawsuits allege the risk–benefit approval process underestimated the 
risk of addiction due to industry’s obfuscation. Tort liability could allocate 
the externalities that result from such a miscalculation to the cheapest cost 
avoider. But market forces in the American healthcare system drive consum-
ers to generic opioids,132 where common law tort claims are preempted un-
126. Opioid Crisis: Are Drug Companies Largely to Blame?, APP. (July 7, 2017, 10:04 AM), 
http://www.app.com/story/opinion/columnists/2017/07/07/opioid-abuse-lawsuit-drug-
companies/103493680/ [https://perma.cc/KG89-EFZZ] (interviewing law professor David 
Noll).
127. Harriet Ryan et al., ‘You Want a Description of Hell?’ Oxycontin’s 12-Hour Problem,
L.A. TIMES (May 5, 2016), http://www.latimes.com/projects/oxycontin-part1/ [https://
perma.cc/5WJS-DJY7]; see Alana Semuels, Are Pharmaceutical Companies to Blame for the 
Opioid Epidemic?, ATLANTIC (June 2, 2017) https://www.theatlantic.com/business/archive/
2017/06/lawsuit-pharmaceutical-companies-opioids/529020/ [https://perma.cc/YQG3-4ZSF]
(explaining that “[t]here is some significant evidence that pharmaceutical companies may have 
engaged in some activities that led to the opioid crisis,” and citing as an example Purdue 
Pharma’s “12-hour” marketing campaign that led consumers to consume the drug in a manner 
that induced addiction).
128. See generally Andrew Westney, Opioid Litigation Roundup: An Overview of Major 
Cases, LAW360 (Oct. 20, 2017, 9:25 PM), https://www.law360.com/articles/975804 (on file with 
the Michigan Law Review).
129. Id.; Robert Storace, CT Unions Sue Nation’s Largest Pharma Companies over Opi-
oids, CONN. L. TRIB. (Dec. 20, 2017, 11:02 PM), https://www.law.com/ctlawtribune/sites/ctlaw
tribune/2017/12/19/4-connecticut-union-locals-file-suit-against-nations-largest-
pharmaceutical-companies/ [https://perma.cc/UU6F-JVYM].
130. Westney, supra note 128; Emily Field, Pharma Cos., States Battle over Opioid Litiga-
tion Transfer, LAW360 (Oct. 24, 2017, 7:20 PM), https://www.law360.com/articles/977356 (on 
file with the Michigan Law Review).
131. See, e.g., Jef Feeley & Jared S. Hopkins, Ohio’s Opioid Suit Should Be Thrown Out, 
Purdue Pharma Argues, BLOOMBERG (Sept. 9, 2017, 3:14 PM), https://www.bloomberg.com/
news/articles/2017-09-09/ohio-s-opioid-suit-should-be-thrown-out-purdue-pharma-argues
[https://perma.cc/23CJ-SYRU] (quoting Purdue’s attorneys who argued that a preemption de-
fense justifies the Ohio lawsuit’s dismissal).
132. Michelle Andrews, Medicare Drug Plans Favor Generic Opioids over Those Designed 
to Avoid Abuse, Study Finds, PBS (June 12, 2015, 12:52 PM), http://www.pbs.org/newshour/
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der Mensing and Bartlett.133 Indeed, the defendants in the opioid litigations 
have already raised blanket preemption defenses.134 Consumers often play 
no role in the decision between a generic or brand-name drug that ends up 
impeding their path to recovery.135 Moreover, the preempted plaintiffs tend 
to be disproportionately low income and more likely to lack access to alter-
native remedies.136
C. Torts Alone Cannot Adequately Compensate the 
Victims of the Opioid Epidemic
Restoring the balance between federal regulation and state common law 
liability in the FDCA’s design would provide a remedy for at least some vic-
tims of this epidemic. That said, merely overruling Mensing and Bartlett
would not provide a comprehensive solution. The vastness of the Opioid Ep-
idemic makes assigning responsibility for the fallout challenging, in both a 
moral and legal sense. The crisis has been shaped by the actions (and inac-
tions) of virtually every stakeholder involved in supplying prescription pain-
rundown/medicare-drug-plans-favor-generic-opioids-designed-avoid-abuse-study-finds/
[https://perma.cc/M3LG-XAZN] (“Medicare drug plans are cutting back on coverage for a 
specially designated type of painkiller that deters abuse in favor of cheaper generics that don’t
have the same deterrent qualities, a new study found.”); see supra note 87 and accompanying 
text; see also Katie Thomas & Charles Ornstein, Amid Opioid Crisis, Insurers Restrict Pricey, 
Less Addictive Painkillers, N.Y. TIMES (Sept. 17, 2017), https://www.nytimes.com/2017/09/17/
health/opioid-painkillers-insurance-companies.html (on file with the Michigan Law Review)
(“At a time when the United States is in the grip of an opioid epidemic, many insurers are lim-
iting access to pain medications that carry a lower risk of addiction or dependence, even as 
they provide comparatively easy access to generic opioid medications.”).
133. See James M. Beck, Generic Drug Preemption Scorecard, DRUG & DEVICE L. (Sept. 
20, 2011), https://www.druganddevicelawblog.com/2011/09/generic-drug-preemption-
scorecard.html [https://perma.cc/J2XQ-D9KJ].
134. See Max Kennerly, Stacking the Deck Against Opioid Plaintiffs, LAW360 (Oct. 24, 
2017, 11:03 AM), https://www.law360.com/articles/977446/ (on file with the Michigan Law 
Review); Nate Raymond, U.S. State, Local Government Lawsuits over Opioids Face Uphill Battle,
REUTERS (June 2, 2017, 7:08 AM), http://www.reuters.com/article/us-ohio-opioids-lawsuit-
analysis/u-s-state-local-government-lawsuits-over-opioids-face-uphill-battle-idUSKBN18
T1H4 [https://perma.cc/9TMN-3A5M] (quoting corporate defense attorneys explaining that 
the FDA’s regulation is the biggest obstacle to opioid litigation against manufacturers).
135. Frequently the prescribing physician, or even the pharmacist, decides whether a pa-
tient will receive the generic or brand-name drug. See PLIVA, Inc. v. Mensing, 564 U.S. 604, 
625 (2011) (“Had [plaintiffs] taken Reglan, the brand-name drug prescribed by their doc-
tors, Wyeth would control and their lawsuits would not be pre-empted. But because pharma-
cists, acting in full accord with state law, substituted generic metoclopramide instead, federal 
law pre-empts these lawsuits.”).
136. See Chen-Sen Wu, Distributive Justice in Pharmaceutical Torts: Justice Where Justice 
Is Due?, 69 L. & CONTEMP. PROBS., Autumn 2006, 207, 212 (2006) (“In . . . [pharmaceutical] 
circumstances, socioeconomic bias may rear its ugly head, whether it is in the form of caregiv-
ers providing more care to wealthier patients . . . or the inability of poorer patients to navigate 
the health care system.”).
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killers: manufacturers,137 distributors,138 physicians and pharmacists,139 in-
surers,140 policymakers,141 and law-enforcement agencies.142
Beyond sheer magnitude, the nature of the harms at issue poses a chal-
lenge for tort plaintiffs. Where addiction is the actionable injury, tort doc-
trine limits feasible arguments. Only “legitimate” use of a prescription opioid 
fits a legal theory that alleges manufacturers misrepresented the addictive 
nature of their drugs and failed to warn consumers.143 Manufacturers have 
succeeded in challenging causality by arguing “that misuse of OxyContin by 
drug abusers was a superseding cause sufficient to break the chain of causa-
tion.”144 For plaintiffs deemed “illegal users” who “intentionally defeated the 
time-release mechanism” of the pill’s design (i.e., crushing the pill, or taking 
137. See Patrick Radden Keefe, The Family That Built an Empire of Pain, NEW YORKER
(Oct. 30, 2017), https://www.newyorker.com/magazine/2017/10/30/the-family-that-built-an-
empire-of-pain [https://perma.cc/53Y3-JNAU] (explaining the history of Purdue and its de-
velopment of OxyContin, including how Purdue lobbied the FDA and medical community to 
support opioid painkillers).
138. See Charles Ornstein, Drug Distributors Penalized for Turning Blind Eye in Opioid 
Epidemic, NPR (Jan. 27, 2017, 5:00 AM), https://www.npr.org/sections/health-shots/2017/01/
27/511858862/drug-distributors-penalized-for-turning-blind-eye-in-opioid-epidemic (on file 
with the Michigan Law Review) (explaining that major pharmaceutical distributors routinely 
fail to report suspicious ordering activity).
139. See John Keilman, Almost All Doctors Routinely Overprescribe Pain Pills: Survey,
CHI. TRIB. (Mar. 24, 2016, 6:20 PM), http://www.chicagotribune.com/news/local/breaking/ct-
prescription-painkiller-overuse-met-20160324-story.html (on file with the Michigan Law Re-
view) (explaining how common healthcare practices have exacerbated the crisis); Brian Krans, 
More ‘Pill Mill’ Doctors Prosecuted amid Opioid Epidemic, HEALTHLINE (May 19, 2016), 
https://www.healthline.com/health-news/pill-mill-doctors-prosecuted-amid-opioid-epidemic
[https://perma.cc/7WL2-DTG2] (explaining how unscrupulous doctors and pharmacies in 
pain clinics—“pill mills”—are a major source of abused medications).
140. See Thomas & Ornstein, supra note 132.
141. See Chris McGreal, How Big Pharma’s Money—and Its Politicians—Feed the US 
Opioid Crisis, GUARDIAN (Oct. 19, 2017, 6:00 AM), https://www.theguardian.com/us-news/
2017/oct/19/big-pharma-money-lobbying-us-opioid-crisis [https://perma.cc/LCN8-MD7V]
(explaining how the pharmaceutical lobby has successfully shaped laws which play a role in the 
ongoing crisis).
142. See Scott Higham & Lenny Bernstein, The Drug Industry’s Triumph over the DEA,
WASH. POST (Oct. 15, 2017), https://www.washingtonpost.com/graphics/2017/investigations/
dea-drug-industry-congress/ [https://perma.cc/VA2W-5HEM]; Bill Whitaker, Ex-DEA Agent: 
Opioid Crisis Fueled by Drug Industry and Congress, 60 MINUTES (Oct. 15, 2017), https://
www.cbsnews.com/news/ex-dea-agent-opioid-crisis-fueled-by-drug-industry-and-congress/
[https://perma.cc/Z2A4-6BY9] (explaining, in part, that political appointees in the DEA adopt-
ed a soft enforcement policy against the pharmaceutical industry at the height of the opioid 
crisis).
143. Joseph B. Prater, Comment, West Virginia’s Painful Settlement: How the Oxycontin 
Phenomenon and Unconventional Theories of Tort Liability May Make Pharmaceutical Com-
panies Liable for Black Markets, 100 NW. U. L. REV. 1409, 1417 (2006) (“Distinguishing be-
tween the harms caused by legitimate use of OxyContin and those caused by its intentional 
abuse is crucial.”).
144. Richard C. Ausness, The Role of Litigation in the Fight Against Prescription Drug 
Abuse, 116 W. VA. L. REV. 1117, 1149 (2014).
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multiple doses), “the extent of their deliberate misuse tended to render any 
sort of claim impracticable.”145 In the class action context, the same issue is 
an obstacle to meeting the standards of Rule 23.146 Some courts have found 
addiction injuries complicate the rule’s commonality and typicality require-
ments because they necessitate “individualized inquiries with respect to 
those class members who crushed or otherwise misused the drug.”147
Causation will be central to any tort action but is likely to exclude addic-
tion injuries. A court’s inquiry into causation and drug abuse is inevitably 
moralistic. Many states’ common law standards will not apply comparative 
negligence frameworks to “intentional abuse of a potentially intoxicating 
substance such as alcohol or OxyContin” but will instead consider this an 
issue of proximate cause.148 The comparison is questionable—not many phy-
sicians prescribe a daily dosage of alcohol in a manner that naturally induces 
physiological addiction and high tolerance.149 By contrast, OxyContin rose 
to prominence on a marketing campaign boasting of twelve-hour pain relief, 
but the drug “wears off hours early in many people,” resulting in “excruciat-
ing symptoms of withdrawal, including an intense craving for the drug.”150
Though addiction science is often hotly contested, it is well-established that 
physiological addiction to opioids, among the most addictive substances 
known to man, impacts decisionmaking processes in the prefrontal cortex.151
Despite this layer of complexity, courts in some of the states most acutely 
impacted by prescription-opioid abuse follow the proximate cause frame-
work and hold illegal drug abuse to be a bar to recovery.152
Therefore, renovating the floor/ceiling model would only partially ad-
dress the problem. The magnitude of the Opioid Epidemic goes beyond the 
personal responsibility of the Americans who have fallen prey to addiction. 
The solution to the problem must do so as well.
145. Prater, supra note 143, at 1419.
146. Ausness, supra note 144, at 1137–46.
147. Id. at 1142–43 (citing Harris v. Purdue Pharma, L.P., 218 F.R.D. 590, 597 (S.D. Ohio 
2003) to show failure on commonality; Campbell v. Purdue Pharma, L.P., No. 1:02cv00163 
TCM, 2004 WL 5840206, at *8–9 (E.D. Mo. June 25, 2004), to show failure on typicality).
148. Labzda v. Purdue Pharma L.P., 292 F. Supp. 2d 1346, 1356 (S.D. Fla. 2003).
149. See W. Michael Hooten et al., Incidence and Risk Factors for Progression from Short-
Term to Episodic or Long-Term Opioid Prescribing: A Population-Based Study, 90 MAYO CLINIC 
PROC. 850 (2015) (finding that over one-in-four patients prescribed opioids on a short-term 
basis for acute pain ended up on longer-term opioid treatment).
150. Ryan et al., supra note 127.
151. See Peter W. Kalivas & Nora D. Volkow, The Neural Basis of Addiction: A Pathology 
of Motivation and Choice, 162 AM. J. PSYCHIATRY 1403, 1408, 1410 (2005) (“The cardinal be-
havioral feature of drug addiction” is vulnerability to “an intense desire for the drug and re-
duced capacity to control that desire” resulting from “profound activation of the prefrontal 
cortex . . . .”).
152. Prater, supra note 143, at 1420 (first citing Labzda, 292 F. Supp. 2d, at 1355–56; then 
citing Foister v. Purdue Pharma, L.P., 295 F. Supp. 2d 693, 704–05 (E.D. Ky. 2003); and then 
citing Orzel v. Scott Drug Co., 537 N.W.2d 208, 212–15 (Mich. 1995)).
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III. Calling for an Opioid Epidemic Victim’s Compensation Fund
In an era where the Supreme Court’s “hostility toward the common law 
of torts trumps even their caustic criticism of the ever-inflating administra-
tive state,” what are the alternative legal mechanisms for internalizing the 
costs of mass injustices like the Opioid Epidemic?153 Section III.A explains 
why alternative solutions, like nontraditional tort schemes or enhanced 
criminal enforcement, would not solve the compensation problem. Section 
III.B proposes an opioid victims’ compensation fund to replicate the original 
vision of the FDCA.
A. Nontraditional Torts and Criminal Punishment 
Cannot Solve This Problem
Beyond optimizing the preemption balance, some possible solutions ex-
ist within nontraditional tort frameworks. For example, in the case of mass-
exposure accidents, injured parties “may in theory sue in tort for redress for 
their injuries,” but in practice “they are unlikely to receive tort compensa-
tion” because “the indeterminacy of causation of the injury[]create[s] a basic 
incongruity with the tort system.”154 Courts can develop novel standards, 
such as the “substantial factor” test, in response to such problems.155 Similar-
ly, the late twentieth century saw a rise in the use of public nuisance doctrine 
to target mass damage resulting from dangerous products, such as tobacco, 
guns, or lead paint.156
Compensating victims of the Opioid Epidemic is likely a challenge that 
even these alternative standards are ill-suited to resolve. While mass-
exposure theory addresses the causation obstacle, ultimately, an FDA-
regulated and doctor-prescribed pharmaceutical drug is neither an environ-
mental nor accidental harm and is ill-suited to the doctrine. Though analo-
gizing between an addictive drug flooding the markets and a toxic substance 
flooding the environment is intriguing, it is probably more useful as a 
thought exercise than a practical litigation strategy.
Public nuisance theory is a closer call. Many legal commentators have 
already begun comparing the tidal wave of opioid litigation to that of the 
1990s tobacco litigation, where public nuisance was utilized.157 The Ohio at-
torney general’s complaint against the opioids manufacturers is testing the 
153. Sharkey, supra note 106, at 1733.
154. Palma J. Strand, Note, The Inapplicability of Traditional Tort Analysis to Environ-
mental Risks: The Example of Toxic Waste Pollution Victim Compensation, 35 STAN. L. REV.
575, 575 (1983).
155. See generally David E. Bernstein, Getting to Causation in Toxic Tort Cases, 74 
BROOK. L. REV. 51 (2008).
156. See Donald G. Gifford, Public Nuisance as a Mass Products Liability Tort, 71 U. CIN.
L. REV. 741 (2003).
157. See, e.g., Richard Scruggs, Are Opioids the New Tobacco?, LAW360 (Sept. 15, 2017, 
11:04 AM), https://www.law360.com/articles/962715/ (on file with the Michigan Law Review).
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theory: its first cause of action is a public nuisance claim.158 Some localities 
have indicated they are taking the same approach.159 But this theory requires 
the extension of a common law doctrine that was virtually never the basis for 
a manufacturer’s liability to an injured consumer until the twenty-first cen-
tury.160 It is unlikely that a majority of courts would welcome such an ap-
proach. Even if public nuisance were a more promising scheme, “the scope 
of liability for damages is more restricted than it is for other torts such as 
strict products liability . . . where compensation is a principal goal.”161 Forc-
ing the common law to serve as a substitute for products liability would fail 
to achieve comprehensive compensation for victims.
Outside of torts, some policymakers argue that an increased criminal 
justice response is needed.162 Indeed, prosecuting corporate executives guilty 
of intentionally or recklessly exacerbating the Opioid Epidemic is likely war-
ranted.163 Law enforcement agencies argue that criminal enforcement im-
proves norms of corporate ethics in the industry, thereby affirmatively re-
ducing the harm done by the epidemic.164
But even when considering that possible shift in corporate culture, in-
creased criminal enforcement could do more harm than good for victims of 
the epidemic. History reflects a tendency for the criminal response to sub-
stance abuse emergencies to take the form of a “war” waged on the same 
158. See Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for 
Fraudulent Marketing; Fueling Opioid Epidemic, OHIO ATT’Y GEN. (May 31, 2017), http://
www.ohioattorneygeneral.gov/Media/News-Releases/May-2017/Attorney-General-DeWine-
Files-Lawsuit-Against-Opio [https://perma.cc/7PG6-59WW].
159. Is the Public Nuisance Universe Expanding?, [Feb. 16, 2017] Envtl. Due Diligence 
Guide Rep. (BNA) No. 26-2, at 16.
160. See Gifford, supra note 156, at 745.
161. Id. at 828.
162. See, e.g., Patricia Baldwin, Prosecutors and Health Care Workers Need Tools to Fight 
Opiate Epidemic, HERALD-TRIB. (Aug. 13, 2017), http://www.batesvilleheraldtribune.com/
opinion/prosecutors-and-health-care-workers-need-tools-to-fight-opiate/article_b2ac6cfc-
c0e5-5a27-9fb3-94f9bba21177.html [https://perma.cc/G6GR-LHG5] (stating that “[p]enalties
for drug possession and dealing are too low” and that public health efforts will fail “without a 
comparable and equivalent improvement on the enforcement side”).
163. See, e.g., Cynthia Koons & Jef Feeley, Opioid Billionaire’s Indictment Opens New 
Window on Epidemic, BLOOMBERG (Oct. 26, 2017, 11:55 AM), https://www.bloomberg.com/
news/articles/2017-10-26/insys-therapeutics-founder-charged-in-opioid-fraud-case [https://
perma.cc/LJH9-VJHX] (describing how billionaire pharmaceutical executive “found an aggres-
sive way to sell even more” opioids by “bribing doctors to prescribe them”).
164. See, e.g., Pharmaceutical Executives Charged in Racketeering Scheme, U.S. DEP’T 
JUST. (Dec. 8, 2016), https://www.justice.gov/usao-ma/pr/pharmaceutical-executives-charged-
racketeering-scheme [https://perma.cc/WVG2-WDVH] (statement of FBI Special Agent Har-
old Shaw) (“[I]ndictments reflect the steadfast commitment of . . . law enforcement . . . to con-
front the opioid epidemic impacting our communities [by] bringing to justice those who seek 
to profit from fraud or other criminal acts.”).
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communities burdened by crisis.165 This aggravates the underlying public 
health problems. The costs of criminal enforcement “disproportionately im-
pact low-income individuals and communities,”166 and “[t]he harms normal-
ly associated with drug addiction . . . are exacerbated in prison.”167 When 
those struggling with addiction are incarcerated, their communities foot the 
bill: a Medical Care study estimates that opioid criminal justice–related costs 
in 2013 totaled $7.7 billion “borne directly by state and local govern-
ments.”168 For opioid addicts not seeking treatment, studies using a “cost-of-
illness methodology” estimate an “average annual law enforcement and vic-
timization societal burden” above $50,000 per individual.169 By contrast, 
“dollar for dollar, treatment” of the underlying addiction “reduces the socie-
tal costs of substance abuse more effectively than incarceration does.”170 Leg-
islators should look to solutions grounded in harm reduction rather than 
criminality when addressing the compensation problem.
B. The Victim’s Compensation Fund Model
A compensation fund has the potential to address the costs problem 
where tort litigation is inadequate and criminal enforcement is counterpro-
ductive. In circumstances where litigation is not feasible or desirable, courts 
and legislatures have turned to the use of compensation funds.171 A compen-
sation fund can mimic the functions of the tort system, achieving goals like 
internalization and deterrence, as well as compensation.172 The fund model 
is a comprehensive approach to public health crises because it “enable[s] 
165. See Lisa D. Moore & Amy Elkavich, Who’s Using and Who’s Doing Time: Incarcera-
tion, the War on Drugs, and Public Health, 98 AM. J. PUB. HEALTH 782 (2008).
166. Melissa S. Kearney, Op-Ed, The Economic Challenges of Crime & Incarceration in the 
United States, BROOKINGS INST. (Dec. 22, 2014), https://www.brookings.edu/opinions/the-
economic-challenges-of-crime-incarceration-in-the-united-states/ [https://perma.cc/6FDD-
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courts to overcome the problems posed by systematic causal indetermina-
cy.”173
Compensation funds are uncommon but not unprecedented.174 The 
best-known compensatory fund is likely the controversial September 11th 
Victim Compensation Fund, “the country’s largest experiment in paying 
mass victims and their families without placing blame.”175 Less well-known
examples exist, including funds addressing childhood vaccine injuries, nu-
clear exposure, black lung disease, and Agent Orange victims.176
The situations above are comparable to the current Opioid Epidemic 
compensation problem. For example, at the apex of the tobacco litigation, 
scholars suggested a variety of compensatory fund approaches as compre-
hensive solutions.177 Similarly, the Childhood Vaccination Compensation 
Program (CVCP) arose when “administratively costly tort liability did not 
provide injured consumers reliable compensation.”178 The CVCP is a close 
analogue to the solution the Opioid Epidemic requires: it “creates something 
of a hybrid system between a fault-based system and a causation-based com-
pensation system” and is “meant to be expeditious . . . accessible, and infor-
mal.”179 CVCP damage awards are funded through an excise tax on the sale 
of the vaccines and, occasionally, additional penalties against manufactur-
ers.180 Like prescription opioids, childhood vaccines provide a clear public 
benefit while also causing injuries that tort liability cannot reliably compen-
sate.181 The opioids compensation fund could also be financed through an 
excise tax, furthering the internalization goal. The CVCP is not primarily 
concerned with deterrence,182 but the opioids fund could additionally 
achieve deterrence goals (against irresponsible marketing, distributing, and 
173. David Rosenberg, The Causal Connection in Mass Exposure Cases: A “Public Law”
Vision of the Tort System, 97 HARV. L. REV. 849, 859 (1984).
174. See Jon D. Hanson, Kyle D. Logue & Michael S. Zamore, Smokers’ Compensation: 
Toward a Blueprint for Federal Regulation of Cigarette Manufacturers, 22 S. ILL. U. L.J. 519, 
535–50 (1998) (providing “ ’real world’ models of . . . compensation programs”).
175. Mullenix & Stewart, supra note 171, at 123 (quoting Amanda Ripley, What Is a Life 
Worth?, To Compensate Victims of Sept. 11, the Government Has Invented a Way to Measure 
Blood and Loss in Cash: A Look at the Wrenching Calculus, TIME, Feb. 11, 2002, at 22).
176. Id. at 133–51.
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to structure a tort-simulating victims’ compensation fund, see Richard C. Ausness, Compensa-
tion for Smoking-Related Injuries: An Alternative to Strict Liability in Tort, 36 WAYNE L. REV.
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179. Id. at 542–43.
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181. See id at 543.
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prescribing) through a partially fault-based component in addition to the tax 
funding.
While funds like the CVCP simply provide cash payouts,183 the opioids 
fund should compensate in a manner that addresses the unique public health 
dimensions of the crisis. For applicants with ongoing addiction injuries at 
the time of application, the fund’s payout schedules could provide sorely 
needed184 drug abuse resources185 rather than cash awards. Harm-reduction 
policies such as overdose-reversal medications, supervised-injection facili-
ties, and addiction-treatment programs should be prioritized to slow the un-
precedented rate of overdose deaths.186 This form of compensation remedies 
the injury at issue and achieves efficiency by relieving over-burdened local 
healthcare systems.187
The fund would be an administrative scheme mimicking products liabil-
ity.188 Industry stakeholders would provide financing, and affected consum-
ers (patients with addiction injuries, families with wrongful death claims, 
etc.) would receive compensation.189 Congress would generate eligibility cri-
teria sufficient to establish an applicant’s injury from a prescription opi-
oid.190 The standard for establishing causation would be cursory by design, 
allowing for compensation beyond what the tort system could achieve and 
deterring manufacturers and distributors from facilitating overprescrip-
tion.191 An administrative tribunal would preside over the fund to evaluate 
183. CVCP applicants can receive “up to $250,000 in pain and suffering damages” and a 
wrongful death fee of $250,000. Id. at 542.
184. See Olga Khazan, Why 80 Percent of Addicts Can’t Get Treatment, ATLANTIC (Oct. 
13, 2015), https://www.theatlantic.com/health/archive/2015/10/why-80-percent-of-addicts-
cant-get-treatment/410269/ [https://perma.cc/DHQ5-WZRJ].
185. See Andrew Kolodny et al., The Prescription Opioid and Heroin Crisis: A Public 
Health Approach to an Epidemic of Addiction, 36 ANN. REV. PUB. HEALTH 559, 569 (2015).
186. See id.; Andrew Lee Ball, HIV, Injecting Drug Use and Harm Reduction: A Public 
Health Response, 102 ADDICTION 684 (2007); see also Phillip O. Coffin & Sean D. Sullivan, 
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ANNALS INTERNAL MED. 1 (2013).
187. See Coffin & Sullivan, supra note 186, at 6 (“Naloxone distribution to heroin users 
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applications and calculate remedies based on predetermined schedules.192
The damages would then be allocated among the opioids manufacturers and 
distributors currently in litigation with state attorneys general.193 Allocations 
would be based on negotiated proportions (depending on the circumstances 
of the negotiations, this could include a fault-based component or simply 
follow market-share). For complying companies, participation in the fund 
would function like a settlement of the pending litigation through its offer of 
prospective tort immunity.194
Thus, an opioids compensation fund could achieve the very functions 
that the post-Mensing-and-Bartlett FDCA floor/ceiling balance cannot. By 
requiring industry participants to finance a portion of the awards, the fund 
imposes the negative-externality costs of opioids on their manufacturers and 
distributors. This internalization reduces inefficiency and alleviates some of 
the macroeconomic burden of the crisis. The more simplistic evaluation of 
causation means the fund would reach a wider population of injured parties. 
The sizable pool of potential applicants also acts as a deterrent against the 
irresponsible prescribing practices that led to the current crisis.
Feasibility is the primary obstacle to this solution. Manufacturers and 
distributors are unlikely to volunteer for new taxes and penalties in exchange 
for tort immunity unless the liability they face is potentially bankrupting. For 
example, during the tobacco litigation policymakers considered compensa-
tion funds while manufacturers were facing potential regulation by the FDA 
and a settlement with state attorneys general estimated at $368.5 billion.195
While comparisons have been made by attorneys familiar with the tobacco 
litigation,196 the current stance of the opioids litigation is not as threatening 
to the pharmaceutical industry.197 Until industry players feel sufficient pres-
sure to come to the table, this solution remains aspirational. But an unprece-
192. See, e.g., Hanson, Logue & Zamore, supra note 174, at 552–53 (discussing the range 
of options for administrators of funds—from “administrative law judges,” to “experts fluent in 
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perma.cc/VUN6-MXJP].
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dented crisis demands unprecedented solutions, and it is not too early to see 
that a compensation fund is an optimal option.
General critics of the compensation fund mechanism may raise concerns 
about manufacturing liability outside of courts. A program like the one sug-
gested here requires “a single, powerful administrator . . . completely domi-
nat[ing] the creation and implementation” of liability imposed upon private 
parties—a system that might “lack[] legitimacy in a democratic society.”198 A
fund simulates the administration of justice in a vacuum removed from “the 
values of participation, accountability, transparency, rationality, personal au-
tonomy, equality, due process, and other social capital values necessary to 
promote civil society.”199
These concerns are justified. But, this kind of remedy is reserved for sit-
uations where existing legal mechanisms are inadequate. Prior examples, 
such as the CVCP or black lung fund, indicate that Congress’s discretion is a 
sufficient barrier to wholesale abandonment of the civil process. Ultimately, 
these criticisms do not outweigh the social value of the fund. A legal system 
that provides no remedy to victims of the Opioid Epidemic is similarly re-
moved from democratic values.
Conclusion
Reasonable minds can disagree on the optimal balance between federal 
regulation and state common law liability in the contemporary administra-
tive state. The FDA’s pharmaceutical regulatory framework, however, indis-
putably relies on some role for the states in compensating consumer injuries. 
Dramatically cutting back that role, just as an unprecedented prescription 
drug crisis grips the nation, protects the pharmaceutical industry’s interests 
at the expense of working Americans.
Allocating costs and compensating injured consumers will alleviate this 
imbalance. The mechanisms of tort liability will force internalization by 
manufacturers and provide needed incentives for safety. But, in a nationwide 
addiction crisis, torts are ill-equipped to achieve this task alone. An Opioid 
Epidemic victims’ compensation fund will achieve this outcome comprehen-
sively.
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